Effect of Dapagliflozin on VT in Patients With Heart Failure.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT05550441

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05550441
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05550441. Randomized; quadruple masking; primary purpose treatment. Start 2022-11-15 (anticipated); primary completion 2024-11-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Dapagliflozin on VT in Patients With Heart Failure.
Condition
Heart Failure
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (class: other)

Record details

Record id
cardio:ct-nct05550441
Content hash
ef8897eb6e3b1b0fef448733eb1d89b222b81c6e868a8aa459b79a1173076a8c